Why the MGC Pharmaceuticals (ASX:MXC) share price is jumping 8%

The MGC Pharmaceuticals (ASX:MXC) share price is surging after the company's drug was passed by two ethics committees. Here's the lowdown.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MGC Pharmaceuticals (ASX: MXC) shares are on the rise today after the company advised two ethics committees have passed its product for phase III clinical trials on COVID-19 patients. At the time of writing, the MGC Pharmaceuticals share price has surged 8% to 8.1 cents.

The pharmaceutical company's CimatrA is designed to target infections with inflammatory complications and has been passed for trials at two separate hospitals.

Let's look take a closer look at the company's news.

Phase III clinical trials

The MGC Pharmaceuticals share price is gaining ground today after the company stated its CimetrA™ product has been approved by two ethics committees. The trials will evaluate the drug's efficacy to treat hospitalised patients diagnosed with moderate COVID-19. It will also provide further data on the use of CimetrA as an investigational medicinal product (IMP).

The trials will take place in Israel, at the Rambam Health Care Campus and Nazareth Hospital EMMS. They are expected to begin next month and be completed by September. Full results are expected to be available in October 2021.

CimetrA has had a name change due to the trial. It was formerly known as ArtemiC™, a name which will live on as a food supplement.

The company states that CimetrA encapsulates technology that delivers active ingredients more effectively in higher concentrations, improving the bioavailability of natural active ingredients.

Commentary from management

Co-founder and managing director of MGC Pharmaceuticals Roby Zomer commented on the ethics committee's approval of CimatrA's stage III trial:

This is a very significant milestone for the Company being the first Phase III clinical trial of CimetrA™. ArtemiC™ has already proven to be a very successful product for the Company, and we look forward to replicating this with CimetrA as an IMP and improve outcomes for COVID-19 patients.

MGC Pharmaceuticals share price snapshot

The MGC Pharmaceuticals share price is having a fantastic year. Currently, the company's shares are up by 350% year to date.

MGC Pharmaceuticals has a market capitalisation of around $170 million, with approximately 2.2 billion shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Woman with a moving box on her head.

1 ASX small-cap stock that could benefit from the rental crisis

Noticed the rental market shortage? This may be an opportunity for this ASX small-cap share.

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.

I'd use the Warren Buffett method and buy these 2 ASX shares

Warren Buffett’s advice has steered me to these stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Broker Notes

This speculative ASX stock could almost double in value

Bell Potter thinks investors could almost double their money with this high risk option.

Read more »

A happy construction worker or miner holds a fistfull of Australian money, indicating a dividends windfall
Share Market News

These ASX 200 mining stocks could rise 30% to 60%

Big returns could be on offer with these miners according to analysts.

Read more »

Scared, wide-eyed man in pink t-shirt with hands covering mouth
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

This ASX 200 stock's 'compelling valuation' makes it a strong buy

Goldman Sachs thinks a 50% return could be on the cards for investors.

Read more »

A man looking at his laptop and thinking.
Share Market News

5 things to watch on the ASX 200 on Monday

Will Aussie investors have a good start to the week? Let's find out.

Read more »

A miner stands in front oh an excavator at a mine site

3 reasons ASX uranium stocks can keep charging higher into 2025

I think the recent sell-down in ASX uranium stocks has been overdone. Here’s why.

Read more »